# **RESEARCH ARTICLE**

**Open Access** 



# Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials

Chenhui Tai<sup>1,2†</sup>, Tianyi Gan<sup>3†</sup>, Liling Zou<sup>4</sup>, Yuxi Sun<sup>5</sup>, Yi Zhang<sup>2</sup>, Wei Chen<sup>2</sup>, Jue Li<sup>4</sup>, Jian Zhang<sup>3</sup>, Yawei Xu<sup>2</sup>, Huihe Lu<sup>1\*</sup> and Dachun Xu<sup>2\*</sup>

# Abstract

**Background:** Heart failure (HF) remains a significant cause of morbidity and mortality. Multiple trials over the past several years have examined the effects of both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after myocardial infarction and in chronic heart failure. Yet, there is still confusion regarding the relative efficacy of rennin-angiotensin-aldosterone system (RAAS) inhibition. Our study was conducted to assess efficacy of ACEIs and ARBs in reducing all-cause and cardiovascular mortality in heart failure patients.

**Methods:** We included randomized clinical trials compared ACEIs and ARBs treatment (any dose or type) with placebo treatment, no treatment, or other anti-HF drugs treatment, reporting cardiovascular or total mortality with an observation period of at least 12 months. Data sources included Pubmed, EMBASE, the Cochrane Central Register of Controlled Trials. Dichotomous outcome data from individual trials were analyzed using the risk ratio measure and its 95%CI with random-effects/ fixed-effects models. We performed meta-regression analyses to identify sources of heterogeneity. All-cause mortality and CV mortality were thought to be the main outcomes.

**Results:** A total of 47,662 subjects were included with a mean/median follow-up ranged from 12 weeks to 4.5 years. Of all 38 studies, 32 compared ACEIs with control therapy (included 13 arms that compared ACEIs with placebo, 10 arms in which the comparator was active treatment and 9 arms that compared ACEIs with ARBs), and six studies compared ARBs with placebo. ACEIs treatment in patients with HF reduced all-cause mortality to 11% (risk ratio (RR): 0.89, 95% confidence interval (CI): 0.83–0.96, p = 0.001) and the corresponding value for cardiovascular mortality was 14% (RR: 0.86, 95% CI: 0.78–0.94, p = 0.001). However, ARBs had no beneficial effect on reducing all-cause and cardiovascular mortality. In head-to-head analysis, ACEIs was not superior to ARBs for all-cause mortality and cardiovascular deaths.

**Conclusions:** In HF patients, ACEIs, but not ARBs reduced all-cause mortality and cardiovascular deaths. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.

Keywords: Heart failure, ACEIs, ARBs, Meta-analysis, Mortality

\* Correspondence: ntdyyyxnk@sina.com; xdc77@aliyun.com

<sup>1</sup>Department of Cardiology, The Second Affiliated Hospital of Nantong

University, 6 Northern Haierxiang Road, Nantong, China

<sup>2</sup>Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, China

Full list of author information is available at the end of the article



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

<sup>&</sup>lt;sup>†</sup>Equal contributors

# Background

Chronic heart failure (HF) has one of the highest morbidity and mortality rates for cardiovascular diseases worldwide, which affects 1-2% of the adult population in developed countries [1]. To lower the risk of adverse clinical outcomes is therefore extremely important in the therapy of this chronic disease.

It is generally accepted that one of the pathophysiological mechanisms of heart failure is excess activation of the rennin angiotensin aldosterone system (RAAS), so that blockade of the RAAS is one of the key therapeutic targets in patients with HF [2–6]. Recent years, a lot of clinical trials have confirmed that suppression of RAAS (angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)) reduces cardiovascular (CV) events in patients with heart failure [7–13].

Moreover, the cardioprotective effects of RAAS were recently called into question. The SOLVD study [5] demonstrated that the addition of enalapril to conventional therapy significantly reduced mortality and hospitalization due to heart failure in HF patients. In the ELITE study [14], it was found that treatment with losartan was associated with lower all-cause mortality than captopril. But, in several head-to-head trials (such as the ELITE II study, the VALIANT study, the RESOLVD study and the OPTIMAAL study), ARBs did not significantly reduce cardiovascular mortality as compared with ACEIS [9–12].

Recent meta-analysis reported that in HF patients with hypertension [15] and diabetes [16], treatment with ACEIs resulted in a significant further reduction in allcause and CV mortality, whereas ARBs had no benefit on these outcomes. These studies indicate that there are different clinical outcomes between ACEIs and ARBs among patients with heart failure.

In light of these conflicting reports, the present metaanalysis was conducted to assess the efficacy of ACEIs and ARBs on all-cause and CV mortality in patients with heart failure.

# Methods

#### Literature search

We searched the database through PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized clinical trials (RCTs) from November 1977 to June 2017 using Medical Subject Heading 'antihypertensive agents' or 'angiotensin II type 1 receptor blockers' or 'angiotensin-converting enzyme inhibitors' and 'heart failure'. Additionally, studies in the reference lists of the identified articles were also hand searched. The search was limited to RCTs, human subjects and English. The process was strict to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISRMA) statement [17].

#### Study eligibility

Studies were deemed eligible if they: 1) were RCTs, targeting HF patients with reduced ejection fraction (HFrEF, left ventricular ejection fraction  $\leq$ 45%), with a median or mean follow-up of more than 12 months; 2) compared ACEIs and ARBs treatment (any dose or type) with placebo treatment, no treatment, or other anti-HF drugs treatment; 3) reported cardiovascular or total mortality. When the outcomes obtained from the same population in different publications, only the latest report was included in the analysis.

#### Data extraction and quality assessment

Two independent investigators (Y. X. and D. X.) extracted data from these reports, and disagreements were resolved by consensus. After excluding the unrelated studies, the following data were extracted: study characteristics (author, publication year, sample size, follow-up period), population baseline characteristics (age, sex, cause of heart failure, risk factors) and end-points. Study quality was assessed using the Jadad score, which is a five-point quality scale, with low quality studies having a score of <2 and high-quality studies a score of  $\geq 3$  [18].

#### Endpoint

All-cause mortality and CV mortality were thought to be the main outcomes.

#### Statistical analysis

Dichotomous outcome data from individual trials was analyzed using the risk ratio (RR) measure and its 95% confidence interval (CI) [19]. Overall effect was estimated using the Mantel-Haenszel method for RRs [20, 21].

Heterogeneity was evaluated using  $\chi^2$  tests and I<sup>2</sup> statistics. Studies were considered statistically heterogeneous if I<sup>2</sup> > 50% and  $p \le 0.05$ . If heterogeneity between studies were identified, a random-effects model was applied. Otherwise, a fixed-effects model was taken instead [22]. Publication bias was assessed with funnel plots and the Begg regression test [22].

In sensitivity analysis, we removed anyone of the study at a time and repeated the meta-analysis to ensure that no single study would be responsible for the significance of any result separately [22].

Meta-regression was conducted to explore the potential heterogeneity related to the participants (age, cause of HF, left ventricular ejection fraction, and follow-up weeks), the agent used (different types). P < 0.05 was considered statistically significant [22].

# Results

#### Eligible studies and baseline characteristics

Initial search identified 1002 reference articles, of these 107 relevant articles were selected and reviewed. Then, several studies were further excluded because they were publications from the same trial (n = 7) or reported of the end points other than cardiovascular events or death (n = 15) or used RAAS inhibitors simultaneously in both trial arms (n = 7) or were not relevant (n = 40). Finally, 38 RCTs assessing the association of cardiovascular outcome or cardiovascular or total mortality with ACEIs or ARBs were included in the meta-analysis [2-14, 22-47]. As shown in Fig. 1, literature research process was summarized by a chart flow. Baseline characteristics of all selected studies are detailed in Table 1. A total of 47,662 subjects were included with a mean/median follow-up ranged from 12 weeks to 4.5 years. Of all 38 studies, six (n = 8404) trials compared ARBs with placebo [13, 43-47], while 32 trials (n = 39,254) compared ACEIs with various control therapies (13 arms (n = 10,134) compared ACEIs [2-6, 23-30] with placebo treatment; 10 arms (n = 8714) in which the Page 3 of 12

comparator was active treatment [7, 8, 31–38]; and 9 arms (n = 20,406) compared ACEIs with ARBs [9–12, 14, 39–42]). Two independent investigators (Y. X. and D. X.) assessed the quality of the studies included. There were 32 studies of good quality (Jadad score  $\geq$  3) with low risk of bias and six studies of low quality (Jadad score < 3) with high risk of bias.

# Effect of ACEIs and ARBs on all-cause mortality

Thirty-two studies [2–12, 14, 23–42] reported the effect of ACEIs on all-cause mortality in a total of 39,254 HF patients with moderate heterogeneity in overall analysis (I<sup>2</sup> = 44%, p = 0.005). ACEIs were associated with a statistically significant 11% reduction in all-cause mortality (RR: 0.89, 95% CI: 0.83–0.96, p = 0.001, Fig. 2). Similar findings were observed when ACEIs were compared with placebo treatment (p < 0.001, Fig. 2). There was no evidence of publication bias (p = 0.833).

Moreover, 15 studies [9–14, 39–47] reported the effect of ARBs on all-cause mortality in a total of 28,814 HF patients with no significant heterogeneity in overall analysis ( $I^2 = 26\%$ , p = 0.17). ARBs were not associated with a reduction in all-cause mortality (RR: 1.03, 95% CI: 0.98–1.08, p = 0.28, Fig. 3). Similar findings were observed when comparing with placebo or ACEIs ( $p \le 0.60$ , Fig. 3). And there was no evidence of publication bias (p = 0.921).




Table 1 Study characteristics																
Study, year	No of nationts	Drugs		Baseline	(1) I		Follow-	Cause (	Cause of heart failure				Risk factors	Ors		- 0
	haurenus	Treatment	Control	Men,%	Age, y	LVEF, %	nh, w	MI, %	HTN,%	ICM, %	NICM, %	VHD, %	DM, %	HTN,%	AF,%	· ·
ARBs vs Controls																
Havranek [43], 1999	218	Irbesartan	Placebo	82	60	≤0.40	12	I	I	67	I	I	I	I	I	
STRETCH [45], 1999	844	Candesartan	Placebo	68	62	0.35-0.45	12	I	29	71	2	2	I	I	I	ম
SPICE [44], 2000	270	Candesartan	Placebo	69	99	<0.35	12	I	4	71	16	11	48	34	24	Ś
ARCH-J [47], 2003	292	Candesartan	Placebo	78	64	≤0.45	24	25	7	I	57	œ	I	Ι	I	4
Val-HeFT [46], 2001	5010	Valsartan	Placebo	80	63	≤0.40	100	I	7	57	31	I	26	I	12	Ś
CHARM-Alternative [13], 2003	2028	Candesartan	Placebo	68	67	≤0.40	135	I	9	68	I	I	27	50	25	Ś
ARBs vs ACEIs																
REPLACE [42], 2001	378	Telmisartan	Enalapril	89	64	≤0.40	12	I	I	I	I	I	I	I	I	4
HEAVEN [40], 2002	141	Valsartan	Enalapril	75	67	≤0.45	12	I	I	87	I	I	T	I	I	ŝ
Dickstein [39], 1995	166	Losartan	Enalapril	78	64	<0.35	12	I	I	69	c	12	I	23	I	ŝ
ELITE [14], 1997	722	Losartan	Captopril	67	73	≤0.40	48	I	I	68	I	I	25	57	23	Ā
ELITE II [10], 2000	3152	Losartan	Captopril	70	71	≤0.40	72	I	I	I	I	I	24	49	30	Ś
RESOLVD [12], 1999	768	Candesartan	Enalapril	84	63	<0.40	43	I	I	72	I	I	I	I	T	Ś
OPTIMAAL [9], 2002	5477	Losartan	Captopril	71	67	<0.35	130	100	0	0	0	0	17	36	10	Ś
VALIANT [11], 2003	14,703	Valsartan	Captopril	69	65	≤0.35-0.45	107	100	0	0	0	0	23	55	I	Ś
Lang [41], 1997	116	Losartan	Enalapril	78	58	≤0.45	12	I	4	47	44	m	I	I	I	$\sim$
ACEIs vs Controls																
AIRE [2], 1993	1986	Ramipril	Placebo	74	65	I	60	I	I	I	I	I	12	28	I	Ś
Balpitt [23], 1998	169	Captopril	Placebo	I	I	I	24	I	I	I	I	I	I	I	I	$\sim$
CASSIS [24], 1995	96	Enalapril	Placebo	83	58	<0.40	12	I	I	70	30	I	23	I	T	$\sim$
Chalmers [25], 1987	130	Lisinopril	Placebo	69	58	I	12	I	13	48	30	~	Ţ	I	I	$\sim$
Colfer [26], 1992	172	Benazepril	Placebo	I	I	≤0.35	12	I	I	I	I	I	Ι	I	I	$\sim$
CONSENSUS [3], 1987	253	Enalapril	Placebo	70	71	I	27	I	I	73	15	26	23	25	58	$\sim$
FEST [27], 1995	308	Fosinopril	Placebo	74	63	≤0.35	12	I	I	I	I	I	I	I	I	4
FHFSG [28], 1995	241	Fosinopril	Placebo	80	62	≤0.35	24	I	I	I	I	I	I	I	I	$\sim$
Lechat [29], 1993	125	Perindopril	Placebo	I	I	I	12	I	I	I	I	I	I	I	I	$\sim$
Newman [30], 1988	105	Captopril	Placebo	I	I	I	12	I	I	I	I	I	I	I	I	$\sim$
SAVE [4], 1992	2231	Captopril	Placebo	82	59	≤0.40	144	100	I	I	I	I	21	43	I	Ś
SOLVD [5], 1991	2569	Enalapril	Placebo	80	61	≤0.35	166	I	I	I	I	I	26	42	10	Ś
TRACE [6], 1995	1749	Trandolapril	Placebo	72	68	≤0.35	96–200	100	I	I	I	I	14	23	Ι	Ś
Aguilar [31], 1999	345	Captopril	Digoxin	68	63	I	216	I	I	I	I	I	I	I	I	3

Ę ž t-Tabla 1

Ś

4 ≥

4 v v

4 m m

4 v v v v w

Jadad Score

Table 1 Study characteristics (Continued)	cs (Continue	(p										
Study, year	No of	Drugs		Baseline	character	Baseline characteristics	Follow- Cause of heart failure	Cause	of heart fa	ailure		
	patients	Treatment Control	Control	Men,%	Age, y	Men,% Age, y LVEF, %	np, w	MI, %	HTN,%	ICM, %	MI, % HTN,% ICM, % NICM, %	-
CARMEN [32], 2008	381	Enalapril	Carvedilol	80	62	<0.40	72	I	I	I	I	· ·
CIBIS III [33], 2011	217	Enalapril	Bisoprolol 7	71 73	73	≤0.35	96	I	25	61	12	

804 V-HeFT II [8], 1991

No number, LVEF left ventricular ejection fraction, MI myocardial infarction, HTN hypertension, DM diabetes mellitus, AF atrial fibrillation, ACE/ angiotensin-converting enzyme inhibitors, ARB angiotensin II Receptor Blockers, ICM ischemic cardiomyopathy, NICM non-ischemic cardiomyopathy, VHD valvular heart disease, m mean Data was absent in the original article

<u>5</u> 1

 $\infty$ 

27 34 24

9 Т 4 T L I

ī ī I

ī. i.

4  $\sim$ 

59 67

99

>40

I

0.2(m)

Hydralazine Omapatrilat

Lisinopril Captopril

<0.40

62 52 2 63 63 6

84 86 89 87 79 I

lbopamine

ī.

Flosequinan

Captopril Captopril

209 266 104 573 45

Dohmen [35], 1997

Cowley [34], 1994

12 58 96

<0.40

ī

i.

ī. i

i

ī.

ī. 1 1 ī.

48 24 32 4

48

20

I

T

I

i.

Ξ

1 I

I. I I

56 T

I

≤0.30

Omapatrilat

5770

Nitrates

Enalapril Enalapril

Candoxatril

Captopril

Northridge [38], 1999 OVERTURE [7], 2002

IMPRESS [37], 2007

Hy-C [36], 1992

< 0.45

Jadad Score 4 Ś m m m Ś  $\sim$ S  $\sim$ 

AF,% 17 54

DM, % HTN,% 32 59

VHD, %

4

1

21

12

**Risk factors** 

1.1.1 Placebo       International and the second seco		ACE	1	Cont	rol		Risk Ratio	Risk Ratio
NIRE 1993       170       1004       222       982       7.2%       0.75 [0.63, 0.60]         Babiti 1998       2       97       1       82       0.1%       1.89 [0.17, 20.40]         Scalin 1995       2       48       6       48       0.2%       0.38 [0.07, 1.57]         Chaimer 1987       4       67       3       43       0.2%       0.68 [0.15, 2.81]         Coller 1992       0       114       3       58       0.1%       0.07 [0.06, 6.76]         EST 1995       5       155       3       165       0.40, 6.76]         EST 1995       0       61       1       64       0.1%       0.35 [0.01, 6.42]         SolvD 1991       452       128       5006       116       0.35 [0.71, 0.97]       9         SolvD 1991       452       128       5006       41.4%       0.82 [0.76, 0.89]       9         SolvDtal (95% CI)       5128       5006       41.4%       0.82 [0.76, 0.89]       9         Coll 1991       132       1475       198       120 [0.85, 1.68]       9         Coll 1991       132       0.85 [0.81, 0.82]       120 [0.85, 1.68]       9         Coll 1991       132       100 </td <td>Study or Subgroup</td> <td>Events</td> <td>Total</td> <td>Events</td> <td>Total</td> <td>Weight</td> <td>M-H, Random, 95% CI</td> <td>M-H, Random, 95% CI</td>	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
$ \begin{array}{c} \text{ALC} 1930 \\ \text{ALC} 1930 \\ \text{AC} 100 \\ \text{COM} 1222 \\ \text{ASSIS 1995 } 2 \\ \text{AB} \\ \text{CASSIS 1995 } 2 \\ \text{CASSIS 1995 } 5 \\ \text{CASSIS 110 } \\ \text{CASSIS 1995 } 5 \\ \text{CASSIS 110 } \\ \text{CASSIS 1995 } 5 \\ \text{CASSIS 1995 } 5 \\ \text{CASSIS 1995 } \\ \text{CASSIS 1995 } 5 \\ \text{CASSIS 1995 } \\ \\ \text{CASSIS 1995 } \\ CASSI$	1.1.1 Placebo							
Balpit 1998 2 67 1 82 0.1% 1.88 [0.17, 20.40] CASIS 1995 2 48 6 48 0.2% 0.68 [0.15, 2.81] Charlines 1987 4 67 3 43 0.2% 0.66 [0.15, 2.81] Conversion 1987 50 127 68 126 4.7% 0.73 [0.56, 0.96] TEST 1995 5 155 3 153 0.3% 1.68 [0.40, 6.76] TEST 1995 3 116 4 122 0.2% 0.81 [0.16, 3.53] Lechal 1993 0 61 1 64 0.1% 0.33 [0.01, 8.42] Sewman TJ 1988 2 53 11 52 0.2% 0.88 [0.6, 0.98] TRACE 1995 3 04 676 369 873 9.6% 0.82 [0.73, 0.93] TRACE 1995 304 676 369 873 9.6% 0.82 [0.73, 0.93] TRACE 1995 304 676 369 873 9.6% 0.82 [0.73, 0.93] TRACE 1995 122 1476 Heterogenety: Tay = 0.00: Ch <sup>2</sup> = 13.79, df = 12 (P = 0.31); P = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.12 Active Aguilar 1999 33 170 49 175 2.8% 0.68 [0.47, 1.02] TARAMEN 2008 14 180 14 191 1.0% 1.01 [0.49, 2.05] Charles 122 1476 Heterogenety: Tay = 0.02: Ch <sup>2</sup> = 14.79 (H = 12, 22% 0.68 [0.47, 1.02] TARAMEN 2008 14 180 14 191 1.0% 1.01 [0.49, 2.05] Charles 122 1476 Heterogenety: Tay = 0.02: Ch <sup>2</sup> = 0.31); P = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.12 Active Aguilar 1999 33 170 49 175 2.8% 0.68 [0.47, 1.02] TARAMEN 2008 14 180 14 191 1.0% 1.01 [0.49, 2.05] TARAMEN 2008 14 180 14 191 1.0% 1.01 [0.49, 2.05] TARAMEN 2008 14 180 14 191 1.0% 0.52 [0.20, 0.97] MPRESS 2007 10 2.84 7 2.89 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 2.84 477 2.88 0.8% 1.07 [0.95, 1.20] MPRESS 2007 12 2.44 7 2.89 0.6% 1.45 [0.56, 3.77] MPRESS 2007 12 2.44 7 2.80 0.45 0.41 7.09 0.80 [0.71, 1.04] Subtotal (95% Cl) 4344 4370 2.27.1% 0.94 [0.80, 1.10] Total avents 772 784 Heterogenetity: Tau <sup>2</sup> = 0.03 (F = 4.69, df = 9 (P = 0.01); P = 39% Test for overall effect: Z = 0.79 (P = 0.43) Tat Association 1.70 1.10 1.1 0.170 1.10 HEAVEN 2002 5 77 1 70 0.1% 4.33 [0.59, 1.13] Heterogenetity: Tau <sup>2</sup> = 0.03 (Ch <sup>2</sup> = 12.46, df = 8 (P = 0.13); P = 36% Test for overall effect: Z = 0.31 (P = 0.002) Total avents 3604 4068 Heterogenetity: Tau <sup>2</sup> = 0.03 (Ch <sup>2</sup> = 0.001) Test for some and for the 2 = 0.31 (P = 0.002) Total exents 3604 4068 Heterogenetity: Tau <sup></sup>	AIRE 1993	170	1004	222	982	7.2%	0.75 [0.63, 0.90]	-
$\begin{aligned} \begin{array}{c} \mbox{ASSIS 1995} & 2 & 48 & 6 & 48 & 0.2\% & 0.35 [0.07, 1.57] \\ \mbox{Charmer 1992} & 0 & 114 & 3 & 58 & 0.1\% & 0.07 [0.05, 1.04] \\ \mbox{ConvSENSUS 1987} & 50 & 127 & 68 & 126 & 4.7\% & 0.07 [0.00, 1.40] \\ \mbox{ConvSENSUS 1987} & 50 & 127 & 68 & 126 & 4.7\% & 0.07 [0.00, 1.40] \\ \mbox{ConvSENSUS 1995} & 50 & 155 & 3 & 153 & 0.3\% & 1.65 [0.40, 6.76] \\ \mbox{HFRSG 1995} & 5 & 155 & 3 & 153 & 0.3\% & 1.65 [0.40, 6.76] \\ \mbox{Lechat 1993} & 0 & 61 & 1 & 64 & 0.1\% & 0.35 [0.01, 8.42] \\ \mbox{Lechat 1993} & 0 & 61 & 1 & 64 & 0.1\% & 0.35 [0.01, 8.42] \\ \mbox{Lechat 1993} & 0 & 61 & 1 & 64 & 0.1\% & 0.35 [0.07, 1.07] \\ \mbox{Lechat 1993} & 0 & 61 & 1 & 64 & 0.1\% & 0.38 [0.04, 0.77] \\ \mbox{SolVE 1992} & 228 & 1115 & 275 & 1116 & 8.2\% & 0.83 [0.71, 0.57] \\ \mbox{Lechat 1995} & 304 & 676 & 386 & 873 & 9.6\% & 0.82 [0.73, 0.33] \\ \mbox{Subtotal (95\% CI)} & 5128 & 5006 & 41.4\% & 0.82 [0.73, 0.33] \\ \mbox{Subtotal (95\% CI)} & 5128 & 5006 & 41.4\% & 0.82 [0.76, 0.89] \\ \mbox{Lol avents} & 1222 & 1476 \\ \mbox{Heterogeneity}; \mbox{Tau}^2 = 0.00; \mbox{Chi}^2 = 13.79, \mbox{df} = 12 (P = 0.31); \mbox{P} = 13\% \\ \mbox{Test for overall effect; Z = 5.01 (P < 0.00001) \\ \mbox{L1.2 Active } & & & & & & & & & & & & & & & & & & $								
Chalmers 1987 4 87 3 43 0.2% 0.68 [0.15, 2.81] Convergence of the second secon	[소리가 가슴, 망망가 방망가 잘못하는							
Coller 1992 0 114 3 58 0.1% 0.07 [0.00, 1.40] CONSENSUS 1997 50 127 68 128 4.7% 0.73 [0.56, 0.96] THESG 1995 5 155 3 153 0.3% 1.65 [0.40, 6.76] CONSENSUS 1997 50 1127 68 128 4.7% 0.73 [0.56, 0.96] THESG 1995 3 116 4 125 0.2% 0.81 [0.18, 3.53] Lechat 1993 0 61 1 4 4 0.1% 0.35 [0.01, 8.42] Newman TJ 1988 2 53 11 52 0.2% 0.81 [0.18, 3.53] SOLVD 1991 452 1285 510 1284 10.4% 0.89 [0.00, 0.88] Subtotal (95% CI) 5128 5006 41.4% 0.82 [0.73, 0.33] Subtotal (95% CI) 5128 5006 41.4% 0.82 [0.76, 0.89] Total events 122 1476 Telerogenetity: Tau" = 0.00; Chi" = 13.79, df = 12 (P = 0.31); P = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.12 Active Applier 1999 33 170 49 175 2.8% 0.68 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] Cardie 1996 13 3 170 49 175 2.8% 0.68 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] Cardie 1999 33 170 49 175 2.8% 0.68 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] Cardie 1999 33 170 49 175 2.8% 0.68 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] Cardie 1999 3 13 152 4.03 0.1% 2.87 [0.30, 27.22] CARMEN 2008 14 190 14 291 71 1.2% 0.83 [0.45, 1.58] Converting 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] MPRESS 2007 10 284 47 289 0.6% 1.45 [0.58, 3.77] WPRESS 2007 10 284 477 2886 9.8% 1.07 [0.95, 1.20] OVERTURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] Cotal events 772 784 Heterogenetity: Tau" = 0.02; Chi" = 14.69, df = 9 (P = 0.10); P = 39% Test for overall effect: Z = 0.79 (P = 0.43) L13 ABB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 1.288] Dickstein 1995 2 58 42 01 078 8.1% 0.90 [0.71, 1.05] Heterogenetity: Tau" = 0.01; Chi" = 12.64, df = 8 (P = 0.13); P = 39% Test for overall effect: Z = 0.81 (P = 0.13); P = 36% Test for overall effect: Z = 0.81 (P = 0.02) Total events 3064 4068 Heterogenetity: Tau" = 0.01; Chi" = 12.64, df = 8 (P = 0.05); P = 44% Total events 1000 1990 4109 20 327 0.5% 0.98 [0.83, 0.96] Total events 3604 4068 Heterogenetity: Tau" = 0.01; Chi" = 12.64, df = 8 (P = 0.05); P								
CONSENSUS 1987 50 127 68 128 4.7% 0.73 [0.56, 0.56] FHFSG 1995 3 116 4 125 0.2% 0.81 [0.18, 3.53] Lechat 1993 0 61 1 64 0.1% 0.35 [0.04, 0.77] SAVE 1992 228 1115 275 1116 8.2% 0.83 [0.71, 0.97] SAVE 1992 228 1115 275 1116 8.2% 0.83 [0.71, 0.97] SAVE 1992 228 1115 275 1116 8.2% 0.83 [0.74, 0.97] SAVE 1992 228 1285 510 1284 10.4% 0.89 [0.80, 0.88] FRACE 1965 304 876 369 873 9.6% 0.82 [0.76, 0.89] FRACE 1965 314 76 369 873 9.6% 0.82 [0.76, 0.89] FRACE 1965 314 70 49 175 2.8% 0.69 [0.47, 1.02] Total avents 1222 1476 Heterogeneity: Tau <sup>2</sup> 0.00; Chi <sup>2</sup> = 13,79, df = 12 (P = 0.31); P = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CHIS III 2011 45 108 38 109 3.4% 1.20 [0.85, 1.68] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] CHIS III 2011 44 28 60 1.3% 0.52 [0.20, 0.97] MPRESS 2007 10 284 477 289 0.6% 1.04 [0.56, 3.77] VCFRTV RE 2002 509 2884 477 288 0.8% 1.07 (0.95, 1.20] VCFRTV RE 2002 509 12 30 0.22 0.1% 2.88 [0.12, 67.03] VCFRTV RE 2002 509 1574 280 1578 8.1% 0.90 [0.77, 1.05] Hator overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 1.288] LITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] LITE II 2000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HATOR 2002 57 71 30 10.2% 1.35 [0.36, 4.1.13] Total avents 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Ch <sup>2</sup> = 14.69, df = 9 (P = 0.19); P = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.56 [0.37, 1.28] LITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] LITE II 2000 2.50 1574 280 1578 8.1% 0.90 [0.00, 1.06] Subtotal (95% CI) 9393 10467 31.4% 0.95 [0.83, 0.96] Total avents 772 774 301 0.2% 1.55 [0.36, 4.1.13] LITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] LITE II 2000 2.5 1574 280 1578 8.1% 0.90 [0.00, 1.06] Subtotal (95% CI) 9393 10467 31.4% 0.95 [0.83, 1.07] Total wents 3064 4068 Heterogeneity:								← · · · · · · · · · · · · · · · · · · ·
EST 1995 5 155 3 153 0.3% 1.65 [0.40, 6.76] HFSG 1995 3 116 4 125 0.2% 0.81 [0.18, 3.53] Lechat 1993 0 61 1 64 0.1% 0.35 [0.01, 8.42] Sechat 1993 0 61 1 64 0.1% 0.35 [0.01, 8.42] Solub 1981 452 1285 510 1284 10.4% 0.89 [0.80, 0.98] FRACE 1995 304 876 369 873 9.6% 0.82 [0.76, 0.89] Total events 1222 1476 Total events 122 19 107 1.2% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CarMeN 2008 14 190 14 191 1.0% 0.69 [0.47, 1.02] CarMeN 2008 14 190 14 191 1.0% 0.69 [0.45, 1.54] Conley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Conter 1997 3 136 1 130 0.1% 2.67 [0.30, 27.22] MMPRESS 2007 10 284 7 289 0.6% 1.45 [0.26, 3.77] Northridge 1999 1 32 0.02 (D.1% 2.68 [0.27, 1.28] Subtotal (95% CI) 124 403 153 401 7.0% 0.86 [0.27, 1.02] WARESS 2007 10 284 477 286 9.8% 0.07 [0.36, 1.60] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.20, 1.10] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.20, 1.10] For all effect: Z = 0.79 (P = 0.43) <b>1.13 ARB</b> DeTime 1997 3 2 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [0.59, 4.13] HI-1998 4 109 2 0.25 1574 280 1578 8.1% 0.90 [0.77, 1.05] HI-2002 5 77 1 1 700 1868 Subtotal (95% CI) 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1998 4 109 20 327 0.5% 0.60 [0.21, 1.72] FEUTH 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 2.70] FUNAL 2002 47 723 499 2744 9.7% 0.90 [0.80, 1.10] FUNAL 2002 477 4 2301 0.2% 1.95 [0.36, 10.47] RESOLVED 1998 4 109 20 327 0.5% 0.60 [0.21, 1.72] FUNAL 2003 958 4909 979 4909 11.2% 0.98 [0.03, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.35, 1.07] FUNAL 2003 958 4909 579 4909 11.2% 0.98 [0.03, 1.06] FUNAL 2004 47 2.03 (1.64, d) f= 3 (P = 0.01); P = 36% Test for overall effect: Z = 0.81 (P = 0.00); CH = 3500, df = 31 (P = 0.03); P = 44% Fertorgeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 5500, df = 31 (P = 0.03); P = 44% Fertorgeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 5500, df = 31 (P = 0								+
$ \begin{array}{c} PHFSG 1995 & 3 & 116 & 4 & 125 & 0.2\% & 0.81 [0.18, 3.53] \\ Lechat 1993 & 0 & 61 & 1 & 64 & 0.1\% & 0.35 [0.01, 8.42] \\ Nerman TJ 1988 & 2 & 53 & 11 & 52 & 0.2\% & 0.18 [0.04, 0.77] \\ SAVE 1992 & 228 & 1115 & 275 & 1116 & 8.2\% & 0.83 [0.71, 0.97] \\ SAVE 1992 & 228 & 1285 & 510 & 1284 & 10.4\% & 0.89 [0.80, 0.98] \\ TRACE 1995 & 304 & 876 & 369 & 873 & 9.6\% & 0.82 [0.73, 0.93] \\ Tratal events & 1222 & 1476 \\ reletorgoeneity : Tau^2 = 0.00; Ch^p = 13.79, df = 12 (P = 0.31); P = 13\% \\ rest for overall effect Z = 5.01 (P < 0.00001) \\ \mathsf{L1.2 Active \\ Aguilar 1999 & 33 & 170 & 49 & 175 & 2.8\% & 0.69 [0.47, 1.02] \\ CARMEN 2008 & 14 & 190 & 14 & 191 & 1.0\% & 1.01 [0.49, 2.05] \\ Colls III 2011 & 45 & 108 & 38 & 109 & 3.4\% & 1.20 [0.85, 1.56] \\ Colls III 2011 & 45 & 102 & 19 & 107 & 1.2\% & 0.83 [0.45, 1.54] \\ Collmen 1997 & 3 & 136 & 1 & 130 & 0.1\% & 2.87 [0.30, 2722] \\ H_{C} C1 1992 & 10 & 44 & 26 & 60 & 1.3\% & 0.52 [0.28, 0.97] \\ Northridge 1999 & 1 & 23 & 0 & 22 & 0.1\% & 2.88 [0.12, 67.03] \\ OVERTURE 2002 & 509 & 2864 & 477 & 286 & 9.6\% & 1.45 [0.56, 3.77] \\ Northridge 1999 & 1 & 23 & 0 & 22 & 0.1\% & 2.88 [0.12, 67.03] \\ OVERTURE 2002 & 509 & 2864 & 477 & 286 & 9.6\% & 1.07 [0.56, 1.20] \\ \mathsf{OVERTURE 2002 & 509 & 2864 & 477 & 286 & 9.6\% & 1.07 [0.50, 1.20] \\ \mathsf{OVERTURE 2002 & 509 & 2864 & 477 & 286 & 9.6\% & 1.07 [0.50, 1.20] \\ \mathsf{NORTHIGE 1995 & 2 & 58 & 2 & 108 & 0.1\% & 1.86 [0.27, 12.88] \\ \mathsf{LITE II 907 & 32 & 370 & 17 & 352 & 1.5\% & 1.79 [1.01, 3.17] \\ ELITE II 907 & 22 & 0.1574 & 280 & 1576 & 8.1\% & 0.90 [0.71, 1.06] \\ \mathsf{HEAVEN 2002 & 5 & 71 & 1 & 70 & 0.1\% & 4.93 [0.59, 41.13] \\ LITE II 999 & 1 & 23 & 70 & 77 & 4 & 301 & 0.2\% & 1.95 [0.36, 1.047] \\ \mathsf{REPLACE 2000 & 2 & 77 & 4 & 301 & 0.2\% & 0.98 [0.80, 1.06] \\ IDAT ALATAT 2003 & 958 & 4009 & 979 & 4099 & 11.2\% & 0.98 [0.90, 1.06] \\ IDAT ALATAT 2003 & 958 & 4009 & 979 & 4099 & 11.2\% & 0.98 [0.83, 0.96] \\ \mathsf{IDATE I 1995 & 10467 & 31.4\% & 0.95 [0.85, 1.07] \\ \mathsf{IDATE I 100 & 100$								
Lechat 1993 0 6 61 1 6 4 0.1% 0.35 [0.01, 8.42] Newman TJ 1988 2 53 11 52 0.2% 0.83 [0.71, 0.97] SOLVD 1991 452 1285 510 1284 10.4% 0.89 [0.80, 0.98] TRACE 1995 304 876 369 873 9.6% 0.82 [0.73, 0.39] Subtotal (95% Cl) 5128 5006 41.4% 0.82 [0.76, 0.89] Total events 1222 1476 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 13.79, df = 12 ( $P = 0.31$ ); $P = 13\%$ Test for overall effect: $Z = 5.01 (P < 0.00001)$ 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2006 14 190 14 191 1.0% 1.01 [0.49, 2.05] Calk Jul 2011 45 108 38 109 3.4% 1.20 [0.85, 1.68] Conversition 1997 3 136 1 130 0.1% 2.87 [0.30, 27, 22] Hy-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] Hy-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] Hy-C 1992 10 284 7 289 0.6% 1.45 [0.26, 3.77] VCHETURE 2002 509 2884 477 286 9.8% 1.07 [0.95, 1.20] VCHETURE 2002 509 2884 477 286 9.8% 1.07 [0.95, 1.20] VCHETURE 2002 509 2884 477 286 9.8% 1.07 [0.95, 1.20] V-HeFT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% Cl) 3344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Ch <sup>2</sup> = 14.69, df = 9 ( $P = 0.10$ ); $P = 39\%$ Test for overall effect: $Z = 0.79 (P = 0.43)$ 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] Dickstein 1995 2 58 2 108 0.1% 1.95 [0.36, 1.01] REJNCE 2000 25 77 1 1 70 0.1% 4.93 [0.59, 1.13] Total events 772 77 4 301 0.2% 1.95 [0.36, 1.047] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 97 9 4999 11.2% 0.98 [0.80, 0.10] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 97 9 4909 11.2% 0.98 [0.83, 0.96] Total events 170 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 55.00, df = 31 ( $P = 0.05$ ); $P = 44\%$ Total events 2601; Ch <sup>2</sup> = 55.00, df = 31 ( $P = 0.05$ ); $P = 36\%$ Test for overall effect: $Z = 3.81 (P = 0.05)$ ; $P = 44\%$ Total events 3604 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 55.00, df = 31 ( $P = 0.05$ ); $P = $								
Newman TJ 1988 2 53 11 52 0.2% 0.18 [0.4, 0.77] SAVE 1992 228 1115 275 1116 8.2% 0.83 [0.71, 0.97] SAVE 1992 228 1115 275 1116 8.2% 0.83 [0.71, 0.97] SAVE 1992 228 1115 275 1116 8.2% 0.83 [0.70, 0.97] SAVE 1992 304 876 369 873 9.6% 0.82 [0.73, 0.93] Trade events 1222 1476 Heterogeneity: Tau <sup>2</sup> = 0.0; Ch <sup>2</sup> = 13.79, df = 12 ( $P = 0.13$ ); $P = 13\%$ Test for overall effect: $Z = 5.01$ ( $P < 0.00001$ ) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CARMEN 2008 14 190 177 1.2% 0.63 [0.45, 1.54] Cohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] 								
SAVE 1992 228 1115 275 1116 8.2% 0.83 [0.71, 0.97] SOLVD 1991 452 1285 510 1284 10.4% 0.89 [0.80, 0.86] SOLVD 1991 452 1285 5006 41.4% 0.82 [0.76, 0.89] Subtotal (95% CI) 5128 5006 41.4% 0.82 [0.76, 0.89] Total events 122 1476 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 13.79, df = 12 (P = 0.31); l <sup>2</sup> = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CarAMEN 2008 14 190 14 191 1.0% 1.01 (0.49, 2.05] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.68] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.64] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.64] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] MPRESS 2007 10 244 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 244 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 244 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 244 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 244 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 244 77 286 0.8% 1.07 [0.51, 1.20] VERTURE 2002 509 2864 477 286 0.8% 1.07 [0.51, 1.20] VERTURE 2002 509 2844 477 286 0.8% 1.07 [0.51, 1.20] VHeFT III 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneily: Tau <sup>2</sup> = 0.02; Ch <sup>2</sup> = 14.69, df = 9 (P = 0.10); l <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dicketin 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] LITE 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] LITE 1997 0 38 6 78 0.1% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] REPLACE 2000 2 77 4 4 301 0.2% 1.95 [0.36, 10.47] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] REPLACE 2000 2 77 4 4 0.97% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 4 0.10 2.75% 0.50 (0.02, 1.72] Total events 1700 1808 Heterogeneily: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 12.46, df = 8 (P = 0.03); l <sup>2</sup> = 36% Test for overall effect: Z = 3.69 (P = 0.00) Faucure screentimeter Z								
SOLVD 1991 452 1285 510 1284 10.4% 0.89 [0.80, 0.99] TRACE 1995 304 876 369 873 9.6% 0.82 [0.73, 0.93] TRACE 1995 304 876 369 873 9.6% 0.82 [0.73, 0.93] Total events 1222 1476 Heterogeneity: Tau* 0.00; Chip = 13.78, df = 12 (P = 0.31); P = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CARMEN 2008 14 190 17 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27, 12] Hy-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 284 77 286 9.8% 1.07 [0.95, 1.20] V-HerT II 1991 132 403 153 401 7.0% 0.68 [0.77, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau* 0.00; C.for 1 4.68, df = 9 (P = 0.10); P = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] Dickstein 1995 2 57 1 1 70 0.1% 4.93 [0.59, 41.13] 								-
TFACE 1995       304       876       369       873       9.6%       0.82 [0.73, 0.93]         Subtotal (95% CI)       5128       5006       41.4%       0.82 [0.76, 0.89]         Teat events       1222       1476         Heterogeneity: Tau" = 0.00; Ch" = 13.79, df = 12 (P = 0.31); P = 13%,         Test for overall effect: Z = 5.01 (P < 0.00001)								
Subtotal (95% CI) 5128 5006 41.4% 0.82 [0.76, 0.89] Total events 1222 1476 Total events 1222 1476 Test for overall effect: $Z = 5.01$ ( $P < 0.0001$ ) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] Callel II 2011 45 108 38 109 3.4% 1.20 [0.85, 1.68] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Cowley AJ 1994 15 102 20 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] Northridge 1999 1 23 0 22 0.1% 2.88 [0.12, 67.03] OVERTURE 2002 509 284 477 2866 9.8% 1.07 [0.95, 1.20] V-HeT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Test for overall effect: $Z = 0.79$ ( $P = 0.43$ ) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 33 6 78 0.1% 0.98 [0.59, 41.13] 								-
Total events 1222 1476 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 13.79, df = 12 (P = 0.31); P = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CIBIS III 2011 45 108 38 109 3.4% 1.20 [0.85, 1.68] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] HV-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.67] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] Northridge 1999 1 23 0 22 0.1% 2.88 [0.12, 67.03] VCHERTURE 2002 509 2884 477 288 0.8% 1.07 [0.95, 1.20] V-HeFT III 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Ch <sup>2</sup> = 14.69, df = 9 (P = 0.10); P = 39% Test for overall effect: Z = 0.79 (P = 0.43) 11.13 ARB Dicketien 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] LITE I12000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.58, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] DPTIMAL 2002 447 2733 499 2744 9.7% 0.94 [0.80, 1.01] DPTIMAL 2002 447 2733 499 274 9.7% 0.96 [0.08, 1.01] DPTIMAL 2002 447 2733 499 274 9.7% 0.96 [0.08, 1.07] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] ALLANT 2003 958 4900 979 4909 11.2% 0.98 [0.90, 10.66] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 700 f108 Heterogeneily: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 2.56, df = 8 (P = 0.13); P = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneily: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 55.00, df = 31 (P = 0.05); P = 44% Test for overall effect: Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneily: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 55.00, df = 31 (P = 0.05); P = 44% Test for overall effect: Z = 0.81 (P = 0.01) Eavours experimental Events control		304		309				•
Heterogeneily: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 13.79, df = 12 (P = 0.31); P = 13% Test for overall effect: Z = 5.01 (P < 0.00001) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] 4.45 [0.56, 3.77] Northridge 1999 1 23 0 22 0.1% 2.88 [0.12, 67.03] OVERTURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] V-teFT II 1991 132 403 153 401 7.0% 0.68 [0.71, 1.04] Subtotal (95% Cl) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); P = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.13 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] LLTE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELTE I 2000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 1.04] AgesDucked 1578 4.99 97 4.99 0.93 (0.10, 1.01] AgesDucked 1578 4.99 97 4.99 0.93 (0.10, 1.01] AgesDucked 1578 4.99 97 4.99 0.5% 0.66 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% Cl) 993 4 109 20 327 0.5% 0.66 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.93, 0.47] Total events 1700 1808 Heterogeneily: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 24.6, df = 8 (P = 0.13); P = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneily: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 25.00, df = 31 (P = 0.05); P = 44% Total events 3694 4068 Heterogeneily: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.05); P = 44% Test for overall effect: Z = 0.81 (P = 0.13); P = 36% Test for overall effect: Z = 0.81 (P = 0.50); D = 44% Test for overall effect: Z = 0.91 (P = 0.50); D = 44% Total events 3694 4068 Heterogeneily: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.05); P = 44% Total events 3694 4068 Heterogeneily: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.05); P		4000	5120	4 4 7 0	5006	41.470	0.02 [0.76, 0.09]	•
Test for overall effect: $Z = 5.01$ (P < 0.00001) 1.1.2 Active Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CARMEN 2008 14 190 19 107 1.2% 0.83 [0.45, 1.58] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dobmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] ty-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 284 4 77 288 9.8% 1.07 [0.95, 1.20] V-HeT III 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); I <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE II 2000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 77 1 1 70 0.1% 4.93 [0.59, 41.13] .ang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] DPTIMAL 2002 2447 2733 499 2744 9.7% 0.90 [0.08, 1.00] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 20, 327 0.5% 0.60 [0.21, 1.72] ALLANT 2003 958 4909 979 4909 11.2% 0.98 [0.08, 0.101] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.68 [0.07, 1.05] UALLANT 2003 958 4909 979 4909 11.2% 0.98 [0.08, 0.106] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.36, 10.47] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 25.60, df = 31 (P = 0.015); I <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total (95% CI) 9411 19843 100.0% 0.89 [0.83, 0.96] Dot 0.1 1 10 100 Favours exercimental Exource experimental Eavours exercimental Exource experimental Eavours exercimental Exource experimental Eavours exercimental Exource experimental Eavours experimental Eavours experimental Exource Experimental Eavours experimental Eavours experimental Eavours experimental Eavours experimental Eavours experimental Eavours experimental Eavours experimental Eavours experimental Eavours experim			- 40 70		(D - 0 0	41.12 - 4004	0	
1.1.2 Active         Aguilar 1999       33       170       49       175       2.8%       0.69       [0.47, 1.02]         CARMEN 2008       14       190       14       191       1.0%       1.01       [0.49, 2.05]         CARMEN 2008       14       190       14       191       1.0%       1.01       [0.49, 2.05]         Consety AJ 1994       15       102       19       107       1.2%       0.83       [0.51, 1.54]         Dohmen 1997       3       136       1       30       0.1%       2.87       [0.30, 27.22]         Hy-C 1992       10       44       26       60       1.3%       0.52       [0.28, 0.97]         Northridge 1999       1       23       0       22       0.1%       2.88       [0.12, 67.03]         OVERTURE 2002       509       2864       477       286       9.8%       1.07       [0.5, 1.20]         V-HeFT II 1991       132       403       153       401       7.0%       0.94       [0.80, 1.10]         Subtotal (95% CI)       4344       4370       27.1%       0.94       [0.80, 1.317]       1.51         ELITE 1997       32       370       17       352					(P = 0.3)	1); $1^{\circ} = 13\%$	D	
Aguilar 1999       33       170       49       175       2.8%       0.69 [0.47, 1.02]         CARMEN 2008       14       190       14       191       1.0%       1.01 [0.49, 2.05]         CARMEN 2008       14       190       14       191       1.0%       1.01 [0.49, 2.05]         CIBIS III 2011       45       108       38       109       3.4%       1.20 [0.45, 1.68]         Cowley AJ 1994       15       102       19       107       1.2%       0.83 [0.45, 1.54]         Dohmen 1997       3       136       1       130       0.1%       2.87 [0.30, 27.22]         MPRESS 2007       10       284       7       289       0.6%       1.45 [0.56, 3.77]         Northridge 1999       1       23       0       22       0.1%       2.88 [0.12, 67.03]         VCHERTURE 2002       509       284       477       286       9.8%       1.07 [0.95, 1.20]         VCHERTURE 2002       509       284       477       286       9.8%       1.07 [0.80, 1.10]         Total events       772       784       +4etorogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); P = 39%       1.5%       1.79 [1.01, 3.17]         ELITE 1997       32       <	lest for overall effect:	Z = 5.01 (F	< 0.00	001)				
Aguilar 1999 33 170 49 175 2.8% 0.69 [0.47, 1.02] CARMEN 2008 14 190 14 191 1.0% 1.01 [0.49, 2.05] CARMEN 2008 14 190 14 191 1.0% 0.83 [0.45, 1.54] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] HV-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] VOERTURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] V-HeFT III 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); I <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] LITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 0 38 6 78 0.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] PTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.80, 0.10] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); I <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); I <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001)	1.1.2 Active							
CARMEN 2008 14 190 14 191 1.0% 1.01 $[0.49, 2.05]$ CIBIS III 2011 45 108 38 109 3.4% 1.20 $[0.85, 1.68]$ CIBIS III 2011 45 102 19 107 1.2% 0.83 $[0.45, 1.54]$ Dohmen 1997 3 136 1 130 0.1% 2.87 $[0.30, 27.22]$ Hy-C 1992 10 44 26 60 1.3% 0.52 $[0.28, 0.97]$ MPRESS 2007 10 284 7 289 0.6% 1.45 $[0.56, 3.77]$ Northridge 1999 1 23 0 22 0.1% 2.88 $[0.12, 67.03]$ OVERTURE 2002 509 2884 477 2886 9.8% 1.07 $[0.95, 1.20]$ V-HeFT II 1991 132 403 153 401 7.0% 0.86 $[0.71, 1.04]$ Subtotal (95% CI) 4344 4 4370 27.1% 0.94 $[0.80, 1.10]$ Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); P = 39% Test for overall effect; Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 $[0.27, 12.88]$ ELITE 1997 32 370 17 352 1.5% 1.79 $[1.01, 3.17]$ ELITE 1997 32 370 17 352 1.5% 1.79 $[1.01, 3.17]$ ELITE 1997 0 38 6 78 0.1% 0.90 $[0.77, 1.05]$ HEAVEN 2002 5 71 1 70 0.1% 4.93 $[0.59, 41.13]$ Lang 1997 0 38 6 78 0.1% 0.16 $[0.01, 2.70]$ OPTIMAAL 2002 247 2733 499 2744 9.7% 0.90 $[0.80, 1.01]$ REPLACE 2000 2 77 4 301 0.2% 1.95 $[0.36, 10.47]$ RESOLVED 1999 4 109 20 327 0.5% 0.60 $[0.21, 1.72]$ VALIANT 2003 958 4909 979 4909 11.2% 0.98 $[0.90, 1.06]$ Subtotal (95% CI) 9939 10467 31.4% 0.95 $[0.83, 0.96]$ Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); P = 36\% Test for overall effect; Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 3 (P = 0.005); P = 44\% Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); P = 44\% Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); P = 44\% Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); P = 44\% Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 51.00, df = 31 (P = 0.005); P = 44\% Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 51.00, df = 31 (P = 0.005); P = 44\% Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 51.00, df = 31 (P = 0.00		33	170	49	175	2.8%	0.69 [0.47, 1.02]	
CIBIS III 2011 45 108 38 109 3.4% 1.20 [0.85, 1.68] Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] Hy-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] OVERTURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] V-HeFT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); I <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 11.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 0 38 6 78 0.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 1.13] DPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 7 77 4 301 0.2% 1.95 [0.36, 1.047] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% CI) 993 10467 31.4% 0.95 [0.85, 1.07] Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); I <sup>2</sup> = 36% Test for overall effect: Z = 3.19 (P = 0.001) Fast yourse generizemental Favourse generize								
Cowley AJ 1994 15 102 19 107 1.2% 0.83 [0.45, 1.54] Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] Hy-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 77 289 0.6% 1.45 [0.56, 3.77] Northridge 1999 1 23 0 22 0.1% 2.88 [0.12, 67.03] OVERTURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] V-HFT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); I <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 197 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 197 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.86, 1.01] Compared to the state of the stat								
Dohmen 1997 3 136 1 130 0.1% 2.87 [0.30, 27.22] +y-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] MPRESS 2007 10 284 47 2886 9.8% 1.07 [0.95, 1.20] -y-EFTURE 2002 509 2884 477 2866 9.8% 1.07 [0.95, 1.20] -y-EFTURE 2002 509 2884 477 2866 9.8% 1.07 [0.95, 1.20] -y-EFTURE 2002 509 2884 477 2866 9.8% 1.07 [0.95, 1.20] -y-EFTURE 2002 509 2884 477 2866 9.8% 1.07 [0.96, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Ch <sup>2</sup> = 14.69, df = 9 (P = 0.10); l <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) <b>1.1.3 ARB</b> Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] -z = 0.02; Ch2 = 14.69, df = 9 (P = 0.10); l2 = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 571 1 70 0.1% 4.93 [0.59, 41.13] $-z = 0.01; Ch2 = 370$ 17 352 1.5% 1.79 [1.01, 3.17] ELITE II 2000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] -z = 0.01; Ch2 = 12.46, df = 8 (P = 0.13); l2 = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total events 1700 1808 Heterogeneity: Tau2 = 0.01; Ch2 = 12.46, df = 8 (P = 0.05); l2 = 44% Test for overall effect: Z = 0.81 (P = 0.001) Evenus eventemental Evenus control 100 Evenus 260, df = 31 (P = 0.005); l2 = 44% Test for overall effect: Z = 3.19 (P = 0.001)								
Hy-C 1992 10 44 26 60 1.3% 0.52 [0.28, 0.97] MPRESS 2007 10 284 7 289 0.6% 1.45 [0.56, 3.77] Northridge 1999 1 23 0 22 0.1% 2.88 [0.12, 67.03] OVERTURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] V-HeFT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); l <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] LLITE II 907 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE II 907 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE II 900 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] .ang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001)								· · · · · · · · · · · · · · · · · · ·
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$							5	
Northridge 1999 1 23 0 22 0.1% 2.88 [0.12, 67.03] DVERURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] V-HeFT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); l <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) <b>1.1.3 ARB</b> Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1900 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.80, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001) Favours experimental Favours control								
DVERTURE 2002 509 2884 477 2886 9.8% 1.07 [0.95, 1.20] V-HeFT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); I <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 112000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] .ang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] DPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.80, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); I <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); I <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001)								
V-HeFT II 1991 132 403 153 401 7.0% 0.86 [0.71, 1.04] Subtotal (95% CI) 4344 4370 27.1% 0.94 [0.80, 1.10] Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); l <sup>2</sup> = 39% Test for overall effect: $Z = 0.79$ (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 112000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: $Z = 0.81$ (P = 0.42) Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: $Z = 3.19$ (P = 0.001) Favours experimental Favours control								
Subtotal (95% CI) 4344 4370 27.1% 0.94 $[0.80, 1.10]$ Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); I <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) <b>1.1.3 ARB</b> Dickstein 1995 2 58 2 108 0.1% 1.86 $[0.27, 12.88]$ LLITE 1997 32 370 17 352 1.5% 1.79 $[1.01, 3.17]$ ELITE 1997 32 370 17 352 1.5% 1.79 $[0.10, 1, 2.70]$ HEAVEN 2002 5 71 1 70 0.1% 4.93 $[0.59, 41.13]$ Lang 1997 0 38 6 78 0.1% 0.90 $[0.80, 1.01]$ REPLACE 2000 2 77 4 301 0.2% 1.95 $[0.86, 10.47]$ RESOLVED 1999 4 109 20 327 0.5% 0.60 $[0.21, 1.72]$ VALIANT 2003 958 4909 979 4909 11.2% 0.98 $[0.90, 1.06]$ Subtotal (95% CI) 9939 10467 31.4% 0.95 $[0.85, 1.07]$ Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); I <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total (95% CI) 19411 19843 100.0% 0.89 $[0.83, 0.96]$ Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); I <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001)								
Total events 772 784 Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); l <sup>2</sup> = 39% Test for overall effect: Z = 0.79 (P = 0.43) 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 11 2000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.86, 10.47] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.86, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% Cl) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total (95% Cl) 19411 19843 100.0% 0.89 [0.83, 0.96] Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001) Favours experimental Expours control		132		153				
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 14.69, df = 9 (P = 0.10); I <sup>2</sup> = 39% Test for overall effect: $Z = 0.79$ (P = 0.43) <b>1.1.3 ARB</b> Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] DPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% Cl) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); I <sup>2</sup> = 36% Test for overall effect: $Z = 0.81$ (P = 0.42) Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.05); I <sup>2</sup> = 44% Test for overall effect: $Z = 3.19$ (P = 0.001) Favours experimental Eavours control		1000	4344		4370	27.1%	0.94 [0.80, 1.10]	
Test for overall effect: $Z = 0.79 (P = 0.43)$ 1.1.3 ARB Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% Cl) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total (95% Cl) 19411 19843 100.0% 0.89 [0.83, 0.96] Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001) Favours experimental Eavours control								
1.1.3 ARB         Dickstein 1995       2       58       2       108 $0.1\%$ 1.86 [0.27, 12.88]         ELITE 1997       32       370       17       352       1.5%       1.79 [1.01, 3.17]         ELITE 1907       32       370       17       352       1.5%       1.79 [1.01, 3.17]         ELITE 1907       32       370       17       352       1.5%       1.79 [1.01, 3.17]         ELITE 19200       250       1574       280       1578       8.1%       0.90 [0.77, 1.05]         HEAVEN 2002       5       71       1       70       0.1%       4.93 [0.59, 41.13]         Lang 1997       0       38       6       78       0.1%       0.90 [0.80, 1.01]         REPLACE 2000       2       77       4       301       0.2%       1.95 [0.36, 10.47]         RESOLVED 1999       4       109       20       327       0.5%       0.60 [0.21, 1.72]         VALIANT 2003       958       4909       979       4909       11.2%       0.98 [0.90, 1.06]         Subtotal (95% Cl)       9939       10467       31.4%       0.95 [0.85, 1.07]       100         Total events       3694       4068       4068<	•				<sup>3</sup> = 0.10	); 1² = 39%		
Dickstein 1995 2 58 2 108 0.1% 1.86 [0.27, 12.88] ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE II 2000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total (95% CI) 19411 19843 100.0% 0.89 [0.83, 0.96] Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001) Favours experimental Eavours control	rest for overall effect.	Z = 0.79 (F	0.43	)				
ELITE 1997 32 370 17 352 1.5% 1.79 [1.01, 3.17] ELITE II 2000 250 1574 280 1578 8.1% 0.90 [0.77, 1.05] HEAVEN 2002 5 71 1 70 0.1% 4.93 [0.59, 41.13] Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total (95% CI) 19411 19843 100.0% 0.89 [0.83, 0.96] Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001) Favours experimental Favours control	1.1.3 ARB							
ELITE II 2000       250       1574       280       1578       8.1%       0.90       [0.77, 1.05]         HEAVEN 2002       5       71       1       70       0.1%       4.93       [0.59, 41.13]         Lang 1997       0       38       6       78       0.1%       0.16       [0.01, 2.70]         OPTIMAAL 2002       447       2733       499       2744       9.7%       0.90       [0.80, 1.01]         REPLACE 2000       2       77       4       301       0.2%       1.95       [0.36, 10.47]         RESOLVED 1999       4       109       20       327       0.5%       0.60       [0.21, 1.72]         VALIANT 2003       958       4909       979       4909       11.2%       0.98       [0.90, 1.06]         Subtotal (95% CI)       9939       10467       31.4%       0.95       [0.85, 1.07]       10         Total (95% CI)       19411       19843       100.0%       0.89       [0.83, 0.96]       10.1       10         Total (95% CI)       19411       19843       100.0%       0.89       [0.83, 0.96]       10.1       10       10         Total events       3694       4068       4068       10.1<	Dickstein 1995	2	58	2	108	0.1%	1.86 [0.27, 12.88]	
HEAVEN 2002       5       71       1       70 $0.1\%$ $4.93 [0.59, 41.13]$ Lang 1997       0       38       6       78 $0.1\%$ $0.16 [0.01, 2.70]$ OPTIMAAL 2002       447       2733       499       2744 $9.7\%$ $0.90 [0.80, 1.01]$ REPLACE 2000       2       77       4 $301$ $0.2\%$ $1.95 [0.36, 10.47]$ RESOLVED 1999       4 $109$ $20$ $327$ $0.5\%$ $0.60 [0.21, 1.72]$ VALIANT 2003       958 $4909$ $979$ $4909$ $11.2\%$ $0.98 [0.90, 1.06]$ Subtotal (95% CI)       9939 $10467$ $31.4\%$ $0.95 [0.85, 1.07]$ Total events       1700 $1808$ Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36\% $0.89 [0.83, 0.96]$ Total (95% CI)       19411       19843       100.0% $0.89 [0.83, 0.96]$ Total (95% CI)       19411       19843       100.0% $0.89 [0.83, 0.96]$ Total events $3694$ $4068$ $0.01$ $0.1$ $1$ $0.01$ $0.1$ $100$ $0.01$ $0.01$ $1$	ELITE 1997	32	370	17	352	1.5%	1.79 [1.01, 3.17]	
Lang 1997 0 38 6 78 0.1% 0.16 [0.01, 2.70] OPTIMAAL 2002 447 2733 499 2744 9.7% 0.90 [0.80, 1.01] REPLACE 2000 2 77 4 301 0.2% 1.95 [0.36, 10.47] RESOLVED 1999 4 109 20 327 0.5% 0.60 [0.21, 1.72] VALIANT 2003 958 4909 979 4909 11.2% 0.98 [0.90, 1.06] Subtotal (95% CI) 9939 10467 31.4% 0.95 [0.85, 1.07] Total events 1700 1808 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36% Test for overall effect: Z = 0.81 (P = 0.42) Total (95% CI) 19411 19843 100.0% 0.89 [0.83, 0.96] Total events 3694 4068 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001) Favours experimental Eavours control	ELITE II 2000	250	1574	280	1578	8.1%	0.90 [0.77, 1.05]	· ·
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	HEAVEN 2002	5	71	1	70	0.1%	4.93 [0.59, 41.13]	· · · · · · · · · · · · · · · · · · ·
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Lang 1997		38	6	78		0.16 [0.01, 2.70]	
REPLACE 2000       2       77       4       301 $0.2\%$ $1.95 [0.36, 10.47]$ RESOLVED 1999       4       109       20       327 $0.5\%$ $0.60 [0.21, 1.72]$ VALIANT 2003       958       4909       979       4909       11.2% $0.98 [0.90, 1.06]$ Subtotal (95% CI)       9939       10467       31.4% $0.95 [0.85, 1.07]$ Total events       1700       1808         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36%         Test for overall effect: Z = 0.81 (P = 0.42)         Total (95% CI)       19411       19843       100.0%       0.89 [0.83, 0.96]         Total events       3694       4068         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%       0.01       0.1       1       10       100         Test for overall effect: Z = 3.19 (P = 0.001)       Favours experimental       Eavours experimental       Eavours control	OPTIMAAL 2002	447		499	2744		2013년 1713년 2013년 2013년 1811년 181 1811년 1811년 1811	
RESOLVED 1999       4       109       20       327 $0.5\%$ $0.60$ $[0.21, 1.72]$ VALIANT 2003       958       4909       979       4909       11.2% $0.98$ $[0.90, 1.06]$ Subtotal (95% CI)       9939       10467       31.4% $0.95$ $[0.85, 1.07]$ Total events       1700       1808         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36%         Test for overall effect: Z = 0.81 (P = 0.42)         Total (95% CI)       19411       19843       100.0%       0.89 [0.83, 0.96]         Total events       3694       4068         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%       0.01       0.1       1       10       100         Test for overall effect: Z = 3.19 (P = 0.001)       Favours experimental       Favours experimental       Favours control								
VALIANT 2003       958       4909       979       4909       11.2%       0.98       [0.90, 1.06]         Subtotal (95% CI)       9939       10467       31.4%       0.95       [0.85, 1.07]         Total events       1700       1808         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36%       0.89       [0.83, 0.96]         Total (95% CI)       19411       19843       100.0%       0.89       [0.83, 0.96]         Total (95% CI)       19411       19843       100.0%       0.89       [0.83, 0.96]         Total events       3694       4068       4068       4068       4068         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%       0.01       0.1       1       10       100         Test for overall effect: Z = 3.19 (P = 0.001)       Favours experimental       Favours experimental       Favours control	RESOLVED 1999							
Subtotal (95% CI)       9939       10467 $31.4\%$ $0.95$ [ $0.85$ , $1.07$ ]         Total events       1700       1808         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36%       0.89 [ $0.83$ , $0.96$ ]         Total (95% CI)       19411       19843       100.0%       0.89 [ $0.83$ , $0.96$ ]         Total events       3694       4068         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%       0.01       0.1       1       10       100         Test for overall effect: Z = 3.19 (P = 0.001)       Favours experimental       Favours experimental       Favours experimental       Favours experimental       Favours experimental	VALIANT 2003							•
Total events       1700       1808         Heterogeneity:       Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36%         Test for overall effect:       Z = 0.81 (P = 0.42)         Total (95% Cl)       19411       19843       100.0%       0.89 [0.83, 0.96]         Total events       3694       4068         Heterogeneity:       Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%       0.01       0.1       1       10       100         Test for overall effect:       Z = 3.19 (P = 0.001)       Eavours experimental       Eavours experimental       Eavours control	Subtotal (95% CI)							•
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 12.46, df = 8 (P = 0.13); l <sup>2</sup> = 36%         Test for overall effect: Z = 0.81 (P = 0.42)         Total (95% Cl)       19411       19843       100.0%       0.89 [0.83, 0.96]         Total events       3694       4068         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%       0.01       0.1       1       10       100         Test for overall effect: Z = 3.19 (P = 0.001)       Favours experimental       Favours experimental       Favours experimental       Favours experimental		1700		1808	1997.02			
Test for overall effect: Z = 0.81 (P = 0.42)         Total (95% Cl)       19411       19843       100.0%       0.89 [0.83, 0.96]         Total events       3694       4068         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%       0.01       0.1       1       10       100         Test for overall effect: Z = 3.19 (P = 0.001)       Eavours experimental       Eavours experimental       Eavours control			= 12 46		P = 0.13	): $ ^2 = 36\%$		
Total events         3694         4068           Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44%         0.01         0.1         1         10         100           Test for overall effect: Z = 3.19 (P = 0.001)         Eavours experimental         Eavours experimental         Eavours control					0.10	/, i = 00 /0		
Total events         3694         4068           Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); I <sup>2</sup> = 44%         0.01         0.1         1         10         100           Test for overall effect: Z = 3.19 (P = 0.001)         Eavours experimental         Eavours control         Eavours experimental         Eavours control								
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 55.00, df = 31 (P = 0.005); l <sup>2</sup> = 44% Test for overall effect: Z = 3.19 (P = 0.001) Favours experimental Favours control			19411		19843	100.0%	0.89 [0.83, 0.96]	1
Test for overall effect: Z = 3.19 (P = 0.001)	Total events							
Test for overall effect: Z = 3.19 (P = 0.001) Eavours experimental Eavours control					(P = 0.0	05); l² = 44	%	
Test for subaroup differences: Chi <sup>2</sup> = 5.69. df = 2 (P = $0.06$ ). I <sup>2</sup> = 64.8%							F	
	Test for subaroup diffe	erences: Ch	ni² = 5.6	9. df = 2 (	P = 0.0	6). I <sup>2</sup> = 64.8	3%	

**Fig. 2** Forest plot of angiotensin-converting enzyme inhibitors (ACEIs) compared with controls on all-cause mortality. Boxes and solid lines indicate RR and 95%CI, respectively for each study, and the diamonds and their width indicate the pooled RR and the 95% CI, respectively. M-H indicates Mantel-Haenszel. ACEI, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker

	ARE	3	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
1.1.1 Placebo							
ARCH-J 2003	2	155	3	150	0.1%	0.65 [0.11, 3.81]	
CHARM-Alternative 2003	265	1013	296	1015	11.9%	0.90 [0.78, 1.03]	
Havranek 1999	3	188	0	30	0.0%	1.15 [0.06, 21.69]	· · · · ·
SPICE 2000	6	179	3	91	0.2%	1.02 [0.26, 3.97]	10 20 20 20
STRETCH 1999	8	366	1	211	0.1%	4.61 [0.58, 36.62]	
Val-HeFT 2001	495	2511	484	2499	19.4%	1.02 [0.91, 1.14]	+
Subtotal (95% CI)		4412		3996	31.7%	0.98 [0.90, 1.07]	•
Total events	779		787				
Heterogeneity: Chi <sup>2</sup> = 4.30,	df = 5 (P =	= 0.51);	$ ^2 = 0\%$				
Test for overall effect: Z = 0	Con Contract ( March 1)						
		<b>- •</b>					
1.1.2 ACEI							
Dickstein 1995	2	108	2	58	0.1%	0.54 [0.08, 3.71]	
ELITE 1997	17	352	32	370	1.3%	0.56 [0.32, 0.99]	
ELITE II 2000	280	1578	250	1574	10.0%	1.12 [0.96, 1.31]	-
HEAVEN 2002	1	70	5	71	0.2%	0.20 [0.02, 1.69]	· · · · · · · · · · · · · · · · · · ·
Lang 1997	6	78	0	38	0.0%	6.42 [0.37, 111.03]	
OPTIMAAL 2002	499	2744	447	2733	18.0%	1.11 [0.99, 1.25]	-
REPLACE 2001	4	301	2	77	0.1%	0.51 [0.10, 2.74]	
RESOLVED 1999	20	327	4	109	0.2%	1.67 [0.58, 4.77]	
VALIANT2003	979	4909	958	4909	38.4%	1.02 [0.94, 1.11]	( <b>#</b> )
Subtotal (95% CI)		10467		9939	68.3%	1.05 [0.99, 1.12]	*
Total events	1808		1700				
Heterogeneity: Chi <sup>2</sup> = 12.46	6, df = 8 (P	= 0.13)	; l <sup>2</sup> = 36%				
Test for overall effect: Z = 1			84 - D.S				
	•						
Total (95% CI)		14879		13935	100.0%	1.03 [0.98, 1.08]	•
Total events	2587		2487				
Heterogeneity: Chi <sup>2</sup> = 18.92	2, df = 14 (l	P = 0.17	'); l <sup>2</sup> = 260	%			
Test for overall effect: Z = 1	.09 (P = 0	.28)				E	avours experimental Favours control
Test for subaroup differenc	es: Chi <sup>2</sup> =	1.83. df	= 1 (P = 0	).18), l <sup>2</sup>	= 45.4%	E	avours experimental Favours control

Fig. 3 Forest plot of angiotensin II receptor blocker inhibitors (ARBs) compared with controls on all-cause mortality. Boxes and solid lines indicate RR and 95%CI, respectively for each study, and the diamonds and their width indicate the pooled RR and the 95% CI, respectively. M-H indicates Mantel-Haenszel. ACEI, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker

Figure 4 showed the relation between the network of RCTs.


#### Effect of ACEIs and ARBs on CV mortality

Seventeen studies [3-6, 8-11, 14, 24, 32, 35, 36, 38, 40-42] reported the effectiveness of ACEIs for CV mortality in a total of 28,302 HF patients with moderate heterogeneity in overall analysis ( $I^2 = 51\%$ , p = 0.009). ACEIs were associated with a statistically significant 14% reduction in CV mortality (RR: 0.86, 95% CI: 0.78–0.94, p = 0.001, Fig. 5). Similar findings were observed when ACEIs treatment was compared with placebo treatment (p < 0.001, Fig. 5). However, when ACEIs were compared with active treatment or ARBs, ACEIs did not significantly reduce CV mortality. There was no evidence of publication bias (p = 0.967). The SAVE [4], TRACE [6] and VALIANT [11] study were conducted in patients with HF after myocardial infarction. After exclusion of these three trials, heterogeneity among the trials was not significantly different ( $I^2 = 34\%$ , p = 0.10, RR, 0.85, 95% CI: 0.76–0.95, *p* = 0.005).

Moreover, 11 studies [9–11, 13, 14, 40–42, 45–47] reported the effectiveness of ARBs for CV mortality in a total of 27,991 HF patients with no significant heterogeneity in overall analysis (I<sup>2</sup> = 40%, p = 0.08). ARBs were associated with no reduction in CV mortality (RR: 1.01, 95% CI: 0.92–1.12, p = 0.78, Additional file 1: Figure S1). Similar findings were observed when ARBs were compared with placebo or ACEIs ( $p \le 0.50$ , Additional file 1: Figure S1). And there was no evidence of publication bias (p = 1.000).

#### **Meta-regression**

Meta-regression was conducted in different ages (p = 0.97), causes of HF (p = 0.90), left ventricular ejection fractions (p = 0.09), follow-up weeks (p = 0.41) to observe effects of ACEIs treatment on all-cause mortality. The findings remained unaltered in these subgroup analyses. But, univariate meta-regression of ACEIs treatment on all-cause mortality varied by the types of ACEIs (p = 0.004). Captopril treatment reduced all-cause mortality by 9% (RR: 0.91, 95% CI: 0.85–0.98, p = 0.008) in



HF patients as compared with control treatment. However, enalapril treatment did not reduce all-cause mortality in HF patients as compared with control treatment (RR: 0.93, 95% CI: 0.85–1.02, p = 0.13, Fig. 6). Of all these studies, one study compared ramipril with placebo and two studies compared lisinopril with placebo/ active drugs. The results were shown in Fig. 5.

# Discussion

# **Major findings**

In this meta-analysis, we combined clinical trial data from 38 studies, which included 47,662 HF patients to assess the efficacy of RAAS inhibition on mortality. Overall, ACEIs reduce all-cause mortality by 11% and the corresponding value for CV mortality by 14%. However, ARBs have no significant effect on all-cause and CV mortality in HF patients. In head-to-head analysis, ACEIs are not superior to ARBs on all-cause and CV mortality. Thus, this meta-analysis provides compelling evidence that ACEIs are the most effective first-line treatment for preventing all-cause and CV mortality in HF patients.

RAAS inhibition has long been identified as a preferred first-line treatment for heart failure. However, previous studies indicated that there were different outcomes between AECIs and ARBs for heart failure. As early as 1987, CONSENSUS study [3] was conducted to evaluate the efficiency of enalapril in patients with HF. Six-month mortality in the enalapril group was 26% compared with 44% in the placebo group, giving a relative risk-reduction of 40% (p = 0.002) and at 1 year, these proportions were 36% and 52% (p = 0.001). After that, several studies demonstrated that ACEIs reduced all-cause and CV mortality in HF patients, particularly after myocardial infarction [4, 6]. However, most of ARBs are not proved to be effective on these crucial outcomes in HF patients. For example, the ELITE II study [10] found that losartan is not superior to captopril, although it has been suggested that the dose of losartan (50 mg) tested is not adequate. And in the CHARM-Alternative trial [13], candesartan did not reduce all-cause mortality in HF patients, but reduced the risk of CV death or HF hospitalization by 23% (p = 0.0004). The Val-Heft study46 showed the same results. These may due to the negative effect of ARBs on heart failure, which could be mediated through a vasoconstrictor-induced increase in blood pressure or a direct effect on cardiac and vascular tissues. So, more related studies are expected to conducted in this area. Besides, in some recent meta-analysis, Vark et al. [15] and Cheng et al. [16] presented that in patients with hypertension and diabetes, treatment with an ACEI resulted in a significant further reduction in all-cause and CV mortality, whereas ARBs had no benefit on these outcomes. These results are in agreement with our meta-analysis.

#### Pharmacological mechanism

From a pharmacological viewpoint, ACEIs can reduce the negative effects caused by binding of angiotensin II and its receptor by inhibiting the conversion of angiotensin I to angiotensin II. In addition, by restraining the degradation of angiotensin (1-7) and promoting its combination with Mas receptor, ACEIs may have effect on dilating blood vessels, anti-inflammatory and antifibrosis. Moreover, ACEIs can also reduce degradation of bradykinin and promote its role in  $\beta 2$  receptor, which contributes to dilation of blood vessels, antiproliferation, endothelial protection and other positive effects [48, 49]. In contrast, RAAS blockade with ARBs is achieved by inhibiting the binding of angiotensin II to the angiotensin II type one receptor, which is believed to


	ACE	El	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random. 95% CI	M-H, Random, 95% CI
.2.1 Placebo							
CASSIS 1995	0	48	6	48	0.1%	0.08 [0.00, 1.33]	<
CONSENSUS 1987	44	127	64	126	6.4%	0.68 [0.51, 0.92]	-
SAVE 1992	188	1115	234	1116	11.1%	0.80 [0.68, 0.96]	-
SOLVD 1991	399	1285	461	1284	14.5%	0.86 [0.78, 0.96]	-
RACE 1995	226	876	288	873	12.5%	0.78 [0.68, 0.91]	<b>T</b>
Subtotal (95% CI)		3451		3447	44.7%	0.81 [0.73, 0.89]	•
Total events	857		1053				
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 5.51,	df = 4 (P	= 0.24);	l <sup>2</sup> = 27%		
est for overall effect:	Z = 4.29 (F	<b>&gt;</b> < 0.00	01)				
.2.2 Active							0
CARMEN 2008	14	190	13	191	1.5%	1.08 [0.52, 2.24]	
Dohmen 1997	3	136	1	130	0.2%	2.87 [0.30, 27.22]	
ly-C 1992	9	44	26	60	1.8%	0.47 [0.25, 0.90]	
Northridge 1999	1	23	0	22	0.1%	2.88 [0.12, 67.03]	· · · · · · · · · · · · · · · · · · ·
-HeFT II 1991	112	403	137	401	9.5%	0.81 [0.66, 1.00]	
ubtotal (95% CI)		796		804	13.1%	0.80 [0.57, 1.11]	•
otal events	139		177				
leterogeneity: Tau <sup>2</sup> =	0.04; Chi <sup>2</sup>	= 5.09,	df = 4 (P	= 0.28);	l² = 21%		
est for overall effect:	Z = 1.34 (F	<b>P</b> = 0.18	)				
.2.3 ARB							
LITE 1997	24	370	12	352	1.7%	1.90 [0.97, 3.75]	2 A
ELITE II 2000	199	1574	230	1578	11.0%	0.87 [0.73, 1.03]	-
IEAVEN 2002	4	71	1	70	0.2%	3.94 [0.45, 34.41]	
ang 1997	0	38	4	78	0.1%	0.23 [0.01, 4.08]	· · · ·
PTIMAAL 2002	363	2733	420	2744	13.4%	0.87 [0.76, 0.99]	
EPLACE 2000	2	77	4	301	0.3%	1.95 [0.36, 10.47]	
ALIANT 2003	830	4909	827	4909	15.6%	1.00 [0.92, 1.10]	. <b>.</b>
ubtotal (95% CI)		9772		10032	42.3%	0.95 [0.83, 1.10]	•
otal events	1422		1498				
eterogeneity: Tau <sup>2</sup> =	0.01; Chi <sup>2</sup>	= 11.73	, df = 6 (F	P = 0.07	); l² = 49%	č.	
est for overall effect:	Z = 0.68 (F	P = 0.50	)				
otal (95% CI)		14019		14283	100.0%	0.86 [0.78, 0.94]	۲
otal events	2418		2728				
leterogeneity: Tau <sup>2</sup> =	0.01; Chi <sup>2</sup>	= 32.53	, df = 16	(P = 0.0	09); l <sup>2</sup> = 5 <sup>-</sup>	1%	0.01 0.1 1 10 10
est for overall effect:	Z = 3.23 (F	<b>P</b> = 0.00	1)			F	avours experimental Favours control
est for subaroup diffe	erences: Cl	hi² = 3.8	3. df = 2 (	P = 0.1	5). I² = 47.	8%	avours experimental Pavours collitor
5 Forest plot of angi	otensin-con	verting	enzyme ir	hibitors	(ACEIs) coi	mpared with controls on c	ardiovascular mortality. Boxes and solid line
cate RR and 95%Cl, re							

indicates Mantel-Haenszel. ACEI, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker

mediate the harmful cardiovascular effects of angiotensin II due to the elevated level of angiotensin II by compensatory mechanism. These different pharmacological mechanisms may explain that ACEIs may be superior to ARBs in reducing CV events. Therefore, an ACEI agent may be a superior ARB antagonist in hypertension and heart failure.

#### Heterogeneity

There was low to moderate heterogeneity of analysis on the effect of ACEIs on all-cause and CV mortality. Meta-regression, sensitivity and subgroup analysis were conducted to estimate the influence of each study. Firstly, no evidence shows that the observed effects varied by age, causes of HF, left ventricular ejection fractions and follow-up weeks by meta-regression. However, different types of ACEIs may influence the effect on all-cause mortality, which means that captopril may be superior to enalapril in reducing all-cause mortality in HF patients. Secondly, the SAVE [4], TRACE [6] and VALIANT [11] study were conducted in patients with heart failure after myocardial infarction. After exclusion of these three trials, heterogeneity among the trials exploring the effect of ACEIs on CV mortality was not significantly different ( $I^2 = 34\%$ , p = 0.10, RR, 0.85, 95% CI: 0.76–0.95, p = 0.005). So, the significant heterogeneity



**Fig. 6** Univariate Meta-regression Analysis of Potential Sources of Heterogeneity on Effect of ACEIs on All-Cause Mortality. Boxes and solid lines indicate RR and 95%Cl, respectively for each study, and the diamonds and their width indicate the pooled RR and the 95% Cl, respectively. Trials to the left of the vertical line showed a reduction in risk with the experimental intervention; those to the right showed an increase in risk with the experimental infraction, HF, heart failure, LVEF, left ventricular ejection fraction

was attributable to the different control treatment. There was no evidence of publication bias (p = 0.721).

#### Study strengths and limitations

Strengths of the present study are no other than the large sample size with a mean/median follow-up ranging from 12 weeks to 4.5 years and a high representativeness.

It has been acknowledged that there are some limitations to this study. Firstly, this analysis used aggregate data as reported or calculated in published articles, rather than data of individual patients. Secondly, there were a great deal of variations between the studied populations. For example, causes of heart failure differed from each other. In addition, these trials used different ACEIs or ARBs at a different dosage. It is likely that different ACEIs and ARBs may have a total different effect on the cardiac mortality. Moreover, the present study is unable to address whether the efficacy may be varied in HF patients with different ethnic backgrounds.

### Conclusions

In 47,662 subjects, our meta-analysis shows that ACEIs, but not ARBs reduce all-cause mortality and cardiovascular deaths in HF patients. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.

### Additional file

Additional file 1: Figure S1. Forest plot of angiotensin II receptor blocker inhibitors (ARBs) compared with controls on cardiovascular mortality. Boxes and solid lines indicate RR and 95%CI, respectively for each study, and the diamonds and their width indicate the pooled RR and the 95% CI, respectively. Trials to the left of the vertical line showed a reduction in risk with the experimental intervention; those to the right showed an increase in risk with the experimental intervention. M-H indicates Mantel-Haenszel. ACEI, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blocker. (TIFF 785 kb)

#### Abbreviations

ACEIs: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II receptor blockers; CI: Confidence interval; CV: Cardiovascular; HF: Heart failure; LVEF: Left ventricular ejection fraction; RAAS: Rennin angiotensin aldosterone system; RCT: Randomized clinical trial; RR: Risk ratio

#### Acknowledgements

The authors thank Dr. Michael Fu from Sahlgrenska Academy, University of Gothenburg for his critical comments and suggestions.

#### Funding

This research was supported by grants from National Natural Science Foundation of China (No. 81270194 and 81,770,391 to Dr. Dachun Xu).

#### Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

#### Authors' contributions

[DX, HL, WC, YS, YZ, LZ, CT, TG, YZ, JL] conception and design of the research. [CT, TG, JZ, YS, WC] acquisition of data. [CT, TG, LZ, JL, WC, YX, YZ] analysis and interpretation for the data. [CT, TG, LZ, JL, YZ, YS, JL] statistical analysis. [DX, HL] obtaining funding and supervising the work. [CT, TG, JZ, WC, LZ, YZ, JL] drafting the manuscript. [DX, HL, WC, YS, TG, JL] critical

revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

#### **Ethics approval and consent to participate** Not applicable.

#### Consent for publication

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Author details

<sup>1</sup>Department of Cardiology, The Second Affiliated Hospital of Nantong University, 6 Northern Haierxiang Road, Nantong, China. <sup>2</sup>Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, China. <sup>3</sup>State Key Laboratory of Cardiovascular Disease, Heart Failure Center Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. <sup>4</sup>Institute of Clinical Epidemiology and Evidence-based Medicine, Tongji University School of Medicine, 1239 Siping Road, Shanghai, China. <sup>5</sup>Department of Cardiology, First Hospital of Lanzhou University, Lanzhou, Gansu, China.

#### Received: 6 July 2017 Accepted: 12 September 2017 Published online: 05 October 2017

#### References

- McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail. 2012;14(8):803–69.
- The Acute Infarction Ramipril Efficacy (AIRE) Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342(8875):821–8.
- CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.
- Pfeffer M, Braunwald E, Moyé L, Basta L, Brown E, Cuddy T, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327(10):669–77.
- Investigators S. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293–302.
- Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting–enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333(25):1670–6.
- Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920–6.
- Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325(5):303–10.
- Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360(9335):752–60.
- Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–7.
- Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20):1893–906.

- McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study: the RESOLVD pilot study investigators. Circulation. 1999;100(10):1056–64.
- Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772–6.
- Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997; 349(9054):747–52.
- van Vark LC, Bertrand M, Akkerhuis KM, Meurers G, Cowley AJ, Thomas I, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin– angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33(16):2088–97.
- Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensinconverting enzyme inhibitors and angiotensin ii receptor blockers on allcause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Inter Med. 2014;174(5):773–85.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
- Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. PharmacoEconomics. 2006;24(1):1–19.
- Higgins JP, Whitehead A. Borrowing strength from external trials in a metaanalysis. Stat Med. 1996;15:2733–49.
- 21. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897–900.
- Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://training.cochrane.org/handbook.
- Bulpitt CJ, Fletcher AE, Dössegger L, Neiss A, Nielsen T, Viergutz S. Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Heart. 1998;79(6):593–8.
- Widimský J, Uhlíř O, Kremer HJ, Jerie P. Czech and Slovak spirapril intervention study (CASSIS). Eur J Clin Pharmacol. 1995;49(1–2):95–102.
- Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol. 1987;9:S89–97.
- Colfer HT, Ribner HS, Gradman A, Hughes CV, Kapoor A, Laidlaw JC. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am J Cardiol. 1992;70(3):354–8.
- Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 1995;16(12):1892–9.
- Brown EJ Jr, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP. BlumenthalM. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol. 1995;75(8):596–600.
- Lechat P, Garnham SP, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J. 1993;126(3):798–806.
- Newman TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, Cooper WH. Effects of captopril on survival in patients with heart failure. Am J Med. 1988;84(3):140–4.
- Cosin-Aguilar J, Marrugat J, Sanz G, Massó J, Gil M, Vargas R, et al. Longterm results of the Spanish trial on treatment and survival of patients with predominantly mild heart failure. J Cardiovasc Pharmacol. 1999;33(5):733–40.
- Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail. 2004;6(4):467–75.
- Funck-Brentano C, Veldhuisen DJ, Ven LLM, Follath F, Goulder M, Willenheimer R. Influence of order and type of drug (bisoprolol vs

enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail. 2011;13(7):765–72.

- Cowley AJ, McEntegart DJ, Hampton JR, Barnett DB, Bexton RS, Boyle R, et al. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. Cardiovasc Drug Ther. 1994; 8(6):829–36.
- Dohmen HJ, Dunselman PH, Poole-Wilson PA. Comparison of captopril and ibopamine in mild to moderate heart failure. Heart. 1997;78(3):285–90.
- Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19(4):842–50.
- Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356(9230):615–20.
- Northridge DB, Currie PF, Newby DE, McMurray JJ, Ford M, Boon NA, Dargie HJ. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail. 1999;1(1):67–72.
- Dickstein K, Chang P, Willenheimer R, Haunsø S, Remes J, Hall C, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26(2):438–45.
- Willenheimer R, Helmers C, Pantev E, Rydberg E, Löfdahl P, Gordon A. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol. 2002;85(2):261–70.
- Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 1997;30(4):983–91.
- 42. Dunselman P. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure: the replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol. 2001; 77(2):131–8.
- Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 1999;33(5):1174–81.
- 44. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensinconverting enzyme inhibitors. Am Heart J. 2000;139(4):609–17.
- Riegger GAJ, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation. 1999;100(22):2224–30.
- Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75.
- 47. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003;5(5):669–77.
- Goussev A, Sharov VG, Shimoyama H, Tanimura M, Lesch M, Goldstein S, et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol. 1998;275(2):H626–31.
- Pahor M, Bernabei R, Sgadari A, Gambassi G Jr, Lo Giudice P, Pacifici L, et al. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension. 1991;18(2):148–57.

# Page 12 of 12

# Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

